Methods of controlling and improving brain health
Inventors
Schaefer, Anne • SULLIVAN, Josefa • TARAKHOVSKY, Alexander • Schaefer, Uwe • Zhang, Tuo
Assignees
Rockefeller University • Icahn School of Medicine at Mount Sinai
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure relates to a method of inducing a neuroprotective state comprising administering a Bromodomain and Extra-Terminal motif (BET) inhibitor under conditions effective to induce a neuroprotective state. Also disclosed are methods of preventing and/or treating neurodegenerative disease, methods of reducing microglial inflammation, and methods of restoring microglial homeostasis, where the methods include administering a Bromodomain and Extra-Terminal motif (BET) inhibitor.
Core Innovation
The disclosure states that pharmacological BET inhibition using brain-permeable BET inhibitors induces a neuroprotective state by blocking BET-dependent transcriptional programs. It further states that pharmacological BET inhibition prevents or treats neurodegenerative diseases by reducing microglial inflammatory activation and restoring microglial homeostasis.
The disclosure describes a mechanistic rationale involving BET regulation of RNAPII pause release via P-TEFb and engagement with acetylated histones, leading to broad transcriptional control. It reports that IBET858 suppresses inflammatory gene programs in microglia while not disrupting microglial identity or homeostatic gene expression.
The disclosure reports that IBET858 is administered to a subject in need thereof for treating Huntington’s disease, and that in neurodegeneration models it reduces microgliosis, preserves neuronal and synaptic markers, and extends survival. It also reports improved neuronal survival against toxic stimuli including glutamate, hypoxia, and Aβ toxicity, together with decreased neuronal metabolism, increased autophagy/proteolysis, and attenuated mTOR activity.
Claims Coverage
The provided content includes one independent claim. The independent claim covers treating Huntington’s disease by administering IBET858 to a subject in need thereof, with dependent claims adding dosage constraints, dosing frequency/duration, and administration routes.
Treating Huntington’s disease by administering IBET858
A method of treating Huntington’s disease comprising administering IBET858 to a subject in need thereof.
IBET858 dosage range for Huntington’s disease treatment
The method further administering IBET858 at a dosage between about 10 mg/kg and about 100 mg/kg.
Once-daily IBET858 administration for about one week
The method further specifying that IBET858 is administered once daily for about one week.
Enumerated routes of administration for IBET858
The method wherein administering is performed by one of several specified routes of administration including intraperitoneal, oral, parenteral, nasally, inhalation, implantation, or application to mucous membranes.
The claim coverage centers on treating Huntington’s disease by administering the BET inhibitor IBET858, with further constraints specifying a dosage range, a once-daily schedule for about one week, and enumerated routes of administration.
Stated Advantages
Induces a neuroprotective state by blocking BET-dependent transcription.
Prevents and/or treats neurodegenerative diseases by reducing microglial inflammatory activation.
Restores microglial homeostasis.
Suppresses inflammatory gene programs in microglia without disrupting microglial identity or homeostatic gene expression.
Reduces microgliosis and preserves neuronal and synaptic markers.
Preserves memory/fear conditioning and extends survival in a Huntington’s model.
Improves neuronal survival against toxic stimuli including glutamate, hypoxia, and Aβ toxicity.
Decreases neuronal metabolism, increases autophagy/proteolysis, and attenuates mTOR activity.
Documented Applications
Treating Huntington’s disease by administering IBET858 to a subject in need thereof.
Preventing or treating neurodegenerative diseases, including Alzheimer’s disease and Huntington’s disease.
Suppressing inflammatory gene programs in microglia while preserving microglial identity and homeostatic gene expression.
Neuroprotection in neurodegeneration models, including reduced microgliosis and preservation of neuronal and synaptic markers.
Rescuing behavioral outcomes such as memory and fear conditioning in AD (p25) and related models.
Extending survival in a Huntington’s disease model (R6/2).
Improving neuronal survival against toxic stimuli including glutamate, hypoxia, and Aβ oligomers.
Interested in licensing this patent?